ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/2071-8713-4799ometendo-4799Research ArticleСтатьиArticlesПервые результаты Российской программы «Апрель» (эффективность применения акарбозы у пациентов с нарушенной толерантностью к глюкозе и артериальной гипертонией)Pervye rezul'taty Rossiyskoy programmy «Aprel'» (effektivnost' primeneniya akarbozy u patsientov s narushennoy tolerantnost'yu k glyukoze i arterial'noy gipertoniey)ChazovaI E-MychkaV B-BelenkovYu N-20051503200521№1 (2005)1318Copyright © Chazova I.E., Mychka V.B., Belenkov Y.N., 20052005Chazova I.E., Mychka V.B., Belenkov Y.N.Chazova I.E., Mychka V.B., Belenkov Y.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/4799ReferencesМычка В.Б., Богиева Р.М., Мамырбаева К.М., Чазова И.Е. Терапия акарбозой как профилактика множественных сердечно-сосудистых факторов риска метаболического синдрома. Артериальная гипертензия 2003;9(2).Мычка В.Б., Богиева Р.М., Мамырбаева К.М., Чазова И.Е. Терапия акарбозой как профилактика множественных сердечно-сосудистых факторов риска метаболического синдрома. Артериальная гипертензия 2003;9(2).Чазова И.Е., Мычка В.Б. Метаболический синдром.Чазова И.Е., Мычка В.Б. Метаболический синдром.DECODE Study Group on behalf of the European Diabetes Epidemiology Group. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European Studies. Diabetologia. 1999;42:654-674.DECODE Study Group on behalf of the European Diabetes Epidemiology Group. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European Studies. Diabetologia. 1999;42:654-674.Dowse G.K., Zimmet P.Z., Gareebo H. et al. Abdominal obesity and physical inac- ti-vity as risk factors for NIDDM and impaired glucose tolerance in Indian, Creole, and Chinese Mauritians. Diabetes Care 1991; 14:271-82.Dowse G.K., Zimmet P.Z., Gareebo H. et al. Abdominal obesity and physical inac- ti-vity as risk factors for NIDDM and impaired glucose tolerance in Indian, Creole, and Chinese Mauritians. Diabetes Care 1991; 14:271-82.Everhart J.E., Petitt D.J., Benneth P.H. et al. Duration of obesity increases the inci- dence of NIDDM. Diabetes 1992; 41:235-240.Everhart J.E., Petitt D.J., Benneth P.H. et al. Duration of obesity increases the inci- dence of NIDDM. Diabetes 1992; 41:235-240.Chiasson J. et al. The STOP-NIDDM trial. An international study on efficacy of an 〈-glucosidase inhibitor to prevent type 2 diabetes in a population with IGT. Diabetes Care, 1998, 21, 1720-1725.Chiasson J. et al. The STOP-NIDDM trial. An international study on efficacy of an 〈-glucosidase inhibitor to prevent type 2 diabetes in a population with IGT. Diabetes Care, 1998, 21, 1720-1725.Howard B. V. Lipoprotein metabolism in diabetes mellitus. J Lipid Res 1987; 28: 613-628.Howard B. V. Lipoprotein metabolism in diabetes mellitus. J Lipid Res 1987; 28: 613-628.Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham Study. Circulation. 1979; 59:8-13.Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham Study. Circulation. 1979; 59:8-13.Malaguarnera Y., Giugno I., Ruello P. et all. Acarbose is an effective adjunct to dietary therapy in the treatment of hypertriglyceridemias. Br J Clin Pharmac 1999; 48: 605-9.Malaguarnera Y., Giugno I., Ruello P. et all. Acarbose is an effective adjunct to dietary therapy in the treatment of hypertriglyceridemias. Br J Clin Pharmac 1999; 48: 605-9.Mamo J., Szeto L., Steiner G. Glycation of very low density lipoprotein from rat plasma impairs its catabolism. Diabetologia 1990; 33:339.Mamo J., Szeto L., Steiner G. Glycation of very low density lipoprotein from rat plasma impairs its catabolism. Diabetologia 1990; 33:339.McKay S.V. et al. Acarbose decreases glucose entry rate and increase glucose oxidation, a U13C-glucose study. Diabetes 1999; 48, suppl V, A 110.McKay S.V. et al. Acarbose decreases glucose entry rate and increase glucose oxidation, a U13C-glucose study. Diabetes 1999; 48, suppl V, A 110.Mikhail N., Golub M., Tuck M. Obesity and hypertension. Prog Cardiovasc Dis 1999; 42 (1): 39-58.Mikhail N., Golub M., Tuck M. Obesity and hypertension. Prog Cardiovasc Dis 1999; 42 (1): 39-58.Rosak C. at al. The effect of the timing and and the administration of acarbose on postprandial hyperglycaemia. Diab Med 1995; 12: 979-84.Rosak C. at al. The effect of the timing and and the administration of acarbose on postprandial hyperglycaemia. Diab Med 1995; 12: 979-84.Stamler J. Epidemic obesity in the United States. Arch Intern Med 1998; 150: 1040-1044.Stamler J. Epidemic obesity in the United States. Arch Intern Med 1998; 150: 1040-1044.Steiner G. Altering triglyceride concentration changes insulin-glucose relation- ships in hypertriglyceridemic patients. Double-blind study with gemfibrozil with implications for atherosclerosis. Diabetes Care 1991; 14:1077-1081.Steiner G. Altering triglyceride concentration changes insulin-glucose relation- ships in hypertriglyceridemic patients. Double-blind study with gemfibrozil with implications for atherosclerosis. Diabetes Care 1991; 14:1077-1081.UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure con-trol and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure con-trol and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
The authors declare that there are no conflicts of interest present.